Allercet-DC

Allercet-DC

Cetirizine Hydrochloride, Phenylephrine Hydrochloride

acute rhinitis (including colds),

allergic rhinitis (including hay fever),

vasomotor rhinitis,

chronic rhinitis,

acute and chronic sinusitis,

acute otitis media (as an auxiliary treatment method),

preparation for surgical interventions in the nasal area and elimination of edema of the nasal mucosa and paranasal sinuses after surgical interventions in this area.

The intranasal route.

For adults, the recommended daily dose is 1-2 injections into each nasal passage 2-3 times a day.

The drug should not be used continuously for more than 7 days.

The bottle should be held vertically, with the spray gun facing up.

Tilt your head, insert the tip of the bottle into the nasal passage, press the nebulizer 1 time with a short sharp movement.

During the injection, it is recommended to take a light breath through the nose. Before the introduction of the drug, the nasal passages should be thoroughly cleaned.

hypersensitivity to phenylephrine, cetirizine or other components of the drug,

atrophic rhinitis,

administration of MAO inhibitors (simultaneous or in the previous 14 days),

angle-closure glaucoma,

pregnancy,

breastfeeding period,

children under 18 years of age (no data on efficacy and safety in children).

With caution: cardiovascular diseases, including arterial hypertension, arrhythmias, generalized atherosclerosis, hyperthyroidism, prostate adenoma, chronic renal failure, elderly age, patients with increased convulsive activity, angina, diabetes mellitus, obstruction of the bladder neck (for example, due to prostatic hypertrophy), epilepsy, patients with severe reactions to sympathomimetics, manifested in the form of insomnia, dizziness, tremor, cardiac arrhythmia, or increased blood pressure (as with any local vasoconstrictor).

Cetirizine in combination with phenylephrine in the form of a spray in therapeutic doses is well tolerated, but the following side effects may occur.

Classification of the frequency of side effects according to WHO recommendations: very often - ≥1/10, often-from ≥1/100 to <1/10, infrequently-from ≥1/1000 to <1/100, rarely-from ≥1/10000 to <1/1000, very rarely - <1/10000, including individual reports, the frequency is unknown — according to available data, it is not possible to determine the frequency of occurrence.

From the blood and lymphatic system: very rarely — thrombocytopenia.

On the part of the immune system: rarely-hypersensitivity reactions, very rarely-anaphylactic shock.

Metabolic and nutritional disorders: frequency unknown-increased appetite.

Mental disorders: infrequently-agitation, rarely-aggression, confusion, depression, hallucinations, sleep disorders, very rarely-tic, frequency unknown-suicidal ideation, sleep disorders (including nightmares).

From the nervous system: infrequently-paresthesia, rarely-convulsions, very rarely - perversion of taste, dyskinesia, dystonia, fainting, tremor, frequency unknown-headache, dizziness, memory impairment, including amnesia, deafness.

On the part of the visual organ: very rarely-a violation of accommodation, blurred vision, nystagmus, the frequency is unknown-vasculitis.

On the part of the organ of hearing and the labyrinth: frequency unknown-vertigo.

From the heart: rarely-tachycardia, frequency unknown-arrhythmia.

From the side of the vessels: the frequency is unknown — increased blood pressure.

Gastrointestinal disorders: infrequently-diarrhea.

From the liver and biliary tract: rarely-hepatic insufficiency with changes in functional liver tests (increased activity of transaminases, alkaline phosphatase, GGT and bilirubin).

From the skin and subcutaneous tissues: infrequently-rash, itching, rarely-urticaria, very rarely-angioedema, persistent drug erythema.

From the side of the muscle, skeletal and connective tissue: the frequency is unknown-arthralgia.

From the kidneys and urinary tract: very rarely — dysuria, the frequency is unknown-urinary retention.

General disorders and reactions at the injection site: infrequently-asthenia, malaise, rarely - discomfort in the nose, dryness or burning in the nose, tingling, sneezing, nosebleeds, frequency unknown-swelling and hyperemia of the nasal mucosa, mucous and watery discharge from the nose, difficulty in nasal breathing. Benzalkonium chloride, which is part of the drug, can cause irritation of the nasal mucosa.

The extremely low systemic absorption of the drug when applied topically makes overdose almost impossible.

Symptoms: confusion, diarrhea, dizziness, fatigue, headache, malaise, mydriasis, itching, restlessness, weakness, sedation, drowsiness, stupor, tachycardia, tremor, urinary retention (with an accidental single oral intake of cetirizine at a dose of 50 mg), cardiac arrhythmias, increased blood pressure, agitation (an overdose of phenylephrine).

Treatment: gastric lavage or stimulation of vomiting, administration of activated charcoal, taking a large amount of fluid, supportive and symptomatic therapy. There is no specific antidote. Hemodialysis is ineffective. In case of overdose, you should consult a doctor.

A combined drug for local intranasal use for pathogenetic and symptomatic treatment, which has a vasoconstrictive and anti-allergic effect.

Phenylephrine is an alpha agonist₁- adrenergic receptors (sympathomimetic), causes narrowing of the blood vessels of the nasal mucosa, reduces swelling of the mucous membranes and tissue hyperemia, congestion in the nasal mucosa. Restoration of the air permeability of the nasopharynx improves the patient's well-being and reduces the risk of possible complications caused by stagnation of the mucous secretion.

Cetirizine-blocker H₁- histamine receptors, has an anti-allergic effect, reduces the permeability of capillaries, prevents the development of edema of the nasal mucosa and its paranasal sinuses.

The composition of the drug includes an auxiliary moisturizing substance glycerol, which helps to retain moisture, which helps to provide hydration in case of dryness and irritation of the nasal mucosa.

The drug is intended for local intranasal use, and its activity does not depend on the concentration of active substances in the blood plasma.

• Combined anti-allergic agents (H₁- histamine receptor blocker alpha-adrenomimetic) [Anticongestants in combinations]

Do not use the drug simultaneously with tri - and tetracyclic antidepressants, beta-blockers, MAO inhibitors (procarbazine, selegiline), maprotilin, guanedrel, guanetidine.

Thyroid hormones with systemic absorption of phenylephrine increase the (mutually) associated risk of coronary insufficiency (especially in coronary atherosclerosis).